Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
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
TUWKEakCtVUHkrba